Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

September 30, 2018

Study Completion Date

December 30, 2018

Conditions
Osteoarthritis, Knee
Interventions
DRUG

Topical tranexamic acid

Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule

DRUG

Floseal®

Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)

DRUG

rivaroxaban (10mg)

Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.

Trial Locations (1)

Unknown

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT03328832 - Combined Topical Tranexamic Acid With Floseal® in Total Knee Arthroplasty | Biotech Hunter | Biotech Hunter